Pulmonx Corp (LUNG) stock
LUNGNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 7/3042% below fair value
$2.73−0.06 (-2.32%)
Close on Nov 17, 2026Market cap $117.46MP/E –Yield –
Pulmonx price to sales ratio
The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.
Pulmonx's price to sales ratio was 1.5× on Nov 11, 2026, against 0.7× a year earlier. Over the last 5 years it ranged from 0.6× to 26.5×, with a median of 4.2×.
Price to Sales Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 1.5× | +0.5 |
| 2025 | Dec 31, 2025 | 1.0× | −2.4 |
| 2024 | Dec 31, 2024 | 3.4× | −4.2 |
| 2023 | Dec 29, 2023 | 7.5× | +1.5 |
| 2022 | Dec 30, 2022 | 6.1× | −20.4 |
| 2021 | Dec 31, 2021 | 26.5× | +18.6 |
| 2020 | Dec 31, 2020 | 7.9× | – |
See a number that looks wrong?